This Weekly Update: July 3
Number of holdings: 11
Summary: This week I sold KYTX to buy ABVX given the risk/reward was immediately skewed to the upside for ABVX whereas KYTX is today partly dependent on mid-stage data later in Q3 sometime. I think ABVX is worth some 38% more than where I purchased this week and could continue. This trade is up 22% already from where I purchased in the last two trading days. July 4th being a trading holiday here, the markets won’t display until Monday the gains indicated may be coming by international markets where this also trades.
DFTX has grown into the top position and I have no interest in trimming/selling going into Phase 3 data in GAD. Long live DFTX! Until they’re bought out that is, for north of $27B is my guess. For LSD. You heard it.
Other News This Week:
ABVX raised $920M through an offering into strength after their last Phase 2 data.
TENX said they will announce data from the Phase 3 trial LEVEL in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026, being held August 28-31 in Munich, Germany.
These weekly developments may fluctuate based on market action, while the catalyst calendar below tracks my expected long-term structural roadmap.
Note for mobile users: This calendar is best viewed in horizontal (landscape) orientation.
Portfolio catalyst calendar
Verified events — May 2026 through 1H 2027
| Date | Position | Catalyst | Impact | Status |
|---|---|---|---|---|
| May 28, 2026 | MDNAF | Offering closes ($0.50/unit, units include warrants at $0.65) | Dilution magnitude locked in | |
| June 3, 2026 | VLTLF | First tonne of lithium carbonate delivered to U.S. industrial customer (Select site) | Moves from production to customer delivery | |
| June 8, 2026 | VLTLF | Lithium carbonate offtake milestone with U.S. industrial customer + ops update | Advances toward binding offtake agreement | |
| June 17, 2026 | QURE | FDA agrees 3-year Phase I/II data acceptable for BLA submission (AMT-130) | Major regulatory reversal, unlocks thesis | UNEXPECTED |
| June 19, 2026 | QURE | AMT-260 Phase I/IIa Cohort 1 data (refractory MTLE) — well-tolerated, early biologic signals | Pipeline validation beyond Huntington's | HIT |
| June 22, 2026 | TSHA | REVEAL Part A 12-month follow-up data (N=12, durable & deepening) | 100% response, milestone gains +94% from 6mo | HIT |
| June 22, 2026 | TSHA | REVEAL Pivotal dosing completion (overenrolled to N=17) | More power vs. null; starts 6-mo clock | |
| June 22, 2026 | DFTX | EMERGE Phase 3 topline (DT120 ODT in MDD) | 8.1-pt MADRS beat, durable to wk 12 | HIT |
| June 23, 2026 | DFTX | Priced upsized $700M offering at $34.00/share (into strength) | Funds commercialization; removes overhang | |
| June 23, 2026 | QURE | Priced upsized offering at $45.50/share ($259M gross, closed June 25) | Funds AMT-130 launch readiness | |
| June 24, 2026 | TSHA | Priced $200M offering at $6.00/share (into strength; closed ~June 26) | Runway into 2H 2028; removes financing overhang | |
| June 29, 2026 | ABVX | ABTECT Maintenance Part 2 topline (refractory UC + safety database) | Malignancy rates in line with background; de-risks NDA | HIT |
| June–July 2026 | TSHA | ASPIRE dosing (overenrolled to N=4, final patient doses in July) | Supports broad label ≥2 years | |
| August 2026 (ESC, Aug 28–31) | TENX | LEVEL Phase 3 topline (230-pt PH-HFpEF, TNX-103) — ESC Munich late-breaker | $50 target trigger | |
| Q3 2026 | QURE | BLA submission for AMT-130 (Huntington's, accelerated approval) | Major QURE binary, approval pathway opens | |
| Q3 2026 | QURE | 4-year AMT-130 data analysis (additional supportive data) | Strengthens BLA + market confidence | |
| Q3 2026 | QURE | MAA submission to UK MHRA (parallel UK regulatory path) | International revenue opportunity | |
| Q3 2026 | DFTX | Voyage Phase 3 topline (DT120 ODT in GAD, 214 pts) | Second DFTX Phase 3 (EMERGE de-risks) | |
| Q3 2026 | IMMX | NEXICART-2 topline (40-pt BLA-enabling, AL amyloidosis) | BLA-enabling, first FDA tx | |
| Late Q3 2026 | DFTX | Panorama Phase 3 topline (DT120 ODT in GAD, 200 pts) | Third DFTX Phase 3 | |
| Q3 2026 | DFTX | DT402 ASD Phase 2a initial data | Pipeline expansion validation | |
| 2H 2026 | MDNAF | MDNA11 expanded clinical data (IL-2 Superkine) | IL-2 thesis validation, M&A trigger | |
| 2H 2026 | IMMX | BLA submission for NXC-201 (after topline) | Approval countdown begins | |
| 2H 2026 | CNVIF | US commercial launch (HiLight intravascular imaging) | Revenue ramp + M&A visibility | |
| 2H 2026 | LUCD | Medicare LCD decision (timing TBD) | 2-3x stock catalyst per thesis | |
| 2H 2026 | QURE | Confirmatory study design finalization with FDA | Removes post-approval uncertainty | |
| Q4 2026 | ABVX | U.S. NDA submission for obefazimod in UC | Regulatory path opens; commercial visibility | |
| Late 2026 | VLTLF | First 1,000-tonne Texas facility commissioning (Select JV) + Texas re-domiciliation toward US listing | Scale-up + institutional access | |
| Sept 30, 2026 | GLSI | Insider lock-up expiration (leak-out plan begins) | Share dynamics shift | |
| Q4 2026 | TSHA | PPQ manufacturing campaign completion | BLA-enabling milestone | |
| Q4 2026 / Q1 2027 | GLSI | 14-event interim analysis (FLAMINGO-01) | Biggest portfolio catalyst | |
| Q4 2026 / Q1 2027 | QURE | BLA acceptance / Priority Review designation | Pre-approval re-rate | |
| 1H 2027 | TSHA | REVEAL 6-month Pivotal interim (slipped from H2 2026 on N=17 overenrollment) | Big TSHA binary, BLA-supporting | |
| Early 2027 | TSHA | FDA meeting to discuss BLA next steps (post-interim gate) | Gates BLA submission timing | |
| Q1 2027 | DFTX | NDA submission for DT120 ODT (EMERGE positive; GAD readouts pending) | Commercial pathway opens | |
| Q1 / Q2 2027 | IMMX | FDA action / Priority Review on NXC-201 BLA | Pre-approval re-rate | |
| Mid-2027 | ABVX | ENHANCE-CD Phase 2b induction topline (obefazimod in Crohn's) | Second indication; expands TAM | |
| Mid-2027 | TSHA | BLA submission (after 1H'27 interim + FDA meeting) | FDA review begins | |
| Mid-2027 | QURE | Potential PDUFA / accelerated approval decision (AMT-130) | Major QURE binary, approval decision | |
| Ongoing | GLSI | Event accumulation updates (toward 14 events) | Triggers interim analysis | — |
Watchlist: Former Holdings
Tracked for potential re-entry as catalysts approach — positions previously held
| Date | Ticker | Catalyst | Re-entry Signal | Status |
|---|---|---|---|---|
| Q2 2026 | VSTM | RAMP 205 expansion cohort update (1L PDAC) | PDAC durability validation | |
| Q2 2026 | HROW | VEVYE sales force fully deployed (90+ new reps) | VEVYE H2 acceleration setup | |
| June 3, 2026 | VSTM | FDA Fast Track Designation for VS-7375 in NSCLC (2nd indication) | Expands commercial opportunity | UNEXPECTED |
| June 23, 2026 | VSTM | TARGET-D 101 updated preliminary data (PDAC, NSCLC, CRC + cetuximab combo) | KRAS G12D validation moment | |
| July 1, 2026 | HROW | BYOOVIZ commercial launch (Lucentis biosimilar) | Retina platform expansion begins | |
| July 1, 2026 | HROW | IOPIDINE 1% permanent J-code effective | Opens 1.5M laser procedures market | |
| Q3 2026 | HROW | BYQLOVI revenue-generating trade launch | Post-surgical steroid market entry | |
| 2H 2026 | VSTM | VS-7375 TARGET-D 101 mature data update | Further KRAS G12D validation | |
| Q3 2026 | KYTX | SPS BLA rolling submission completion | First autoimmune CAR-T to file; approval countdown | |
| Q4 2026 | HROW | QUELL trial topline (IHEEZO indication expansion) | IHEEZO label broadening | |
| Q4 2026 | HROW | G-MELT renal/hepatic impairment studies complete | NDA package finalizing | |
| Q1 / Q2 2027 | KYTX | Potential SPS approval (Priority Review timeline) | First FDA autoimmune CAR-T — key re-entry signal | |
| January 2027 | HROW | OPUVIZ commercial launch (Eylea biosimilar) | $12B market entry — key re-entry signal | |
| Q1 2027 | HROW | G-MELT NDA submission (sublingual sedation) | 5M cataract surgeries TAM | |
| Q2 2027 | HROW | BYQLOVI NDA submission (next-gen topical steroid) | First new molecule in class in 15+ yrs | |
| Mid-2027 | VSTM | RAMP 301 Phase 3 topline (recurrent LGSOC) | Major VSTM binary — key re-entry signal |
Highlighted rows = top portfolio-impact catalysts (active) or key re-entry signals (watchlist) | HIT = positive readout
Compiled May 18, 2026 — last updated July 4, 2026